WINTON GROUP Ltd boosted its position in shares of AbbVie Inc (NYSE:ABBV) by 48.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 146,505 shares of the company’s stock after acquiring an additional 47,980 shares during the period. WINTON GROUP Ltd’s holdings in AbbVie were worth $10,623,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Acropolis Investment Management LLC purchased a new position in shares of AbbVie in the second quarter worth $106,000. Ffcm LLC raised its holdings in shares of AbbVie by 167.2% in the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after buying an additional 963 shares during the last quarter. Hudock Capital Group LLC raised its holdings in shares of AbbVie by 109.5% in the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after buying an additional 806 shares during the last quarter. BDO Wealth Advisors LLC purchased a new position in shares of AbbVie in the second quarter worth $115,000. Finally, Franklin Parlapiano Turner & Welch LLC purchased a new position in shares of AbbVie in the first quarter worth $108,000. 69.32% of the stock is owned by institutional investors.

A number of analysts have recently weighed in on ABBV shares. Jefferies Group increased their price objective on shares of AbbVie from $107.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. BMO Capital Markets set a $66.00 price objective on shares of AbbVie and gave the stock a “hold” rating in a research note on Friday, October 27th. BidaskClub upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 6th. Piper Jaffray Companies raised their price target on shares of AbbVie to $115.00 and gave the company an “overweight” rating in a research report on Friday, October 27th. Finally, SunTrust Banks restated a “buy” rating on shares of AbbVie in a research report on Monday, October 30th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $97.96.

In other news, VP Robert A. Michael sold 6,699 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $88.00, for a total value of $589,512.00. Following the sale, the vice president now directly owns 10,007 shares of the company’s stock, valued at approximately $880,616. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Severino sold 25,633 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the completion of the sale, the executive vice president now directly owns 114,922 shares in the company, valued at $10,881,964.18. The disclosure for this sale can be found here. Insiders have sold 268,825 shares of company stock worth $25,186,090 over the last ninety days. 0.23% of the stock is owned by insiders.

AbbVie Inc (ABBV) opened at $97.35 on Thursday. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. AbbVie Inc has a 52 week low of $59.27 and a 52 week high of $98.87. The firm has a market cap of $153,736.20, a PE ratio of 18.14, a PEG ratio of 1.34 and a beta of 1.52.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 27th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The company had revenue of $7 billion for the quarter, compared to the consensus estimate of $7 billion. During the same period in the previous year, the firm earned $1.21 earnings per share. AbbVie’s quarterly revenue was up 8.8% compared to the same quarter last year. research analysts anticipate that AbbVie Inc will post 5.55 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Thursday, January 11th. This is an increase from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a yield of 2.92%. AbbVie’s payout ratio is 62.29%.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/winton-group-ltd-acquires-47980-shares-of-abbvie-inc-abbv/1763219.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.